Targeting MDM2 by the small molecule RITA: towards the development of new multi-target drugs against cancer
© Espinoza-Fonseca; licensee BioMed Central Ltd. 2005
Received: 11 July 2005
Accepted: 20 September 2005
Published: 20 September 2005
The use of low-molecular-weight, non-peptidic molecules that disrupt the interaction between the p53 tumor suppressor and its negative regulator MDM2 has provided a promising alternative for the treatment of different types of cancer. Among these compounds, RITA (reactivation of p53 and induction of tumor cell apoptosis) has been shown to be effective in the selective induction of apoptosis, and this effect is due to its binding to the p53 tumor suppressor. Since biological systems are highly dynamic and MDM2 may bind to different regions of p53, new alternatives should be explored. On this basis, the computational "blind docking" approach was employed in this study to see whether RITA would bind to MDM2.
It was observed that RITA binds to the MDM2 p53 transactivation domain-binding cleft. Thus, RITA can be used as a lead compound for designing improved "multi-target" drugs. This novel strategy could provide enormous benefits to enable effective anti-cancer strategies.
This study has demonstrated that a single molecule can target at least two different proteins related to the same disease.
Keywordsmulti-target drugs RITA cancer treatment blind docking MDM2 p53 tumor suppressor
The p53 tumor suppressor is one of the principal mediators of cell-cycle arrest and the activation of apoptosis in response to a broad array of cellular injuries [1–4]. In normal unstressed cells, p53 is regulated by a feedback loop with the negative regulator protein MDM2 (murine double-minute clone 2, referred to as human double-minute clone 2, HDM2, in humans) [1, 2, 5]. A well-known mechanism for the loss of wild-type p53 activity in cancer cells is the overexpression of MDM2, which leads to constitutive inhibition of p53 and thus allows the tumor cells to escape from p53-induced apoptosis .
In the present study the computational "blind docking" approach  is used in order to determine the possibility of RITA binding and its preferential binding sites. It was found not only that RITA can bind efficiently to the MDM2 p53 transactivation domain-binding cleft, but also that is highly specific for its binding site. The results of this study support the effectiveness of the "multi-target" approach in anti-cancer drug design.
Results and discussion
The objective of this study was to demonstrate that RITA, a drug originally found to bind the p53 tumor suppressor, is also able to bind at the MDM2-p53 transactivation domain-binding cleft, which increases its effectiveness and makes it a lead compound for further anti-cancer drug design efforts.
Calculated free energy of binding of RITA obtained through the blind and fine docking experiments. Kd is the computed dissociation constant, focc is the number of results in the top clusters; Ntot is the number of clusters generated by AutoDock.
Type of docking
As mentioned in the introduction, RITA was previously found to bind to the p53 tumor suppressor, which induces its accumulation in tumor cells and leads to selective apoptosis . It was hypothesized that RITA behaved as an allosteric modulator, inducing conformational changes in p53 and preventing it from binding MDM2 but preserving its functional role. Unfortunately, the full structure of the p53 tumor suppressor is not available, which impedes global screening of the best RITA binding site. Nevertheless, there is enough experimental evidence showing that RITA binds to p53. This work demonstrates that RITA could also bind to the MDM2-p53 transactivation domain-binding cleft.
An important point to consider is that it was shown experimentally that RITA does not bind to MDM2 . Nevertheless it was found in this study that the base structure of the compound (the 2,5-di-thiophen-2-yl-furan moiety) was able to bind to the p53-binding cleft. Preliminary docking studies on different NMR structures of MDM2 showed that RITA can actually bind to the same binding cleft over different MDM2 conformations. This suggests that RITA itself might not be a potent MDM2 inhibitor, but the binding affinity for both MDM2 and p53 might be improved by modifying its structure. The apparent inability of RITA to bind to MDM2 in experiments might be due to the need for high concentrations of this compound to attain effective inhibition. This possibility correlates well with our docking simulations, in which the computed dissociation constant of RITA binding to MDM2 is relatively high.
The experimental Kd obtained for RITA binding to p53 is 1.5 nM, while the computed Kd of RITA binding to MDM2 is 22 μM. This means that RITA binds some ~15000 times more tightly to p53 than to MDM2. Thus, to use RITA as is would be problematic in principle, since much higher concentrations would be necessary to target both p53 and MDM2 efficiently. The physiological consequences are obvious. On this basis, it is proposed in this study that RITA could be markedly improved to increase its effectiveness on MDM2, while retaining its effectiveness on p53. Thus, structural modifications in RITA would alleviate the lack of selectivity for MDM2, making it an effective multi-target drug.
To visualize the approach presented here better, the following factors should be kept in mind: a) biomolecules are not static entities but are constantly involved in dynamic processes; b) MDM2 displays important conformational transitions when binding to different fragments of the N-terminal domain of p53  and can interact with the core domain of the latter [21, 22]; c) p53 may mutate in key residues, hindering RITA binding but not altering its physiological role; d) as pointed by Van Regenmortel, the binding site should not be visualized without considering the binding partner ; and e) as remarked by Weaver and co-workers, a promiscuous drug candidate is not a collection of different molecules acting in combination on different receptors implicated in the pathogenesis of a disease, but rather a single molecule capable of binding to a range (albeit a limited range) of targets . Thus, improved RITA derivatives could bind not only to p53 but also to MDM2, which would increase or reinforce its therapeutic effect. In other words, the "multi-target" behavior observed by these compounds would compensate their therapeutic deficiencies because of the dynamic nature of the targets involved and the observed promiscuity of MDM2 over p53. Thereby, RITA could serve as a lead compound for designing improved, low-toxicity and highly effective apoptosis inducers via p53 activation and facilitating the effective inhibition of p53 ubiquitination by MDM2. Its effectiveness would then be improved by its action on multiple pathways related to the disease .
Currently, additional simulations are being carried out that allow MDM2 to flex, in order to sample the conformational space more thoroughly, and modifications of the RITA structure are in course. These simulations will help to determine the structural keys involved in the molecular recognition mechanism, to modify the structure of RITA and to improve the activity of a new family of potent anti-cancer drugs.
The aim of the present study was to support the viability of the multi-target approach in the design of anti-cancer drugs. For this purpose, a recently described system, the MDM2-p53 complex, was successfully used as a study model.
"Blind" and "fine" docking simulations using the AutoDock program revealed that RITA, a molecule originally investigated for binding to the p53 tumor suppressor, can also bind to the MDM2 p53 transactivation domain-binding cleft. As a multi-target drug acting on several proteins related to the same disease, RITA could be more therapeutically effective in the treatment of some types of cancer. These findings open a new and exciting perspective for effective cancer treatment with low-molecular-weight, non-peptidic molecules.
Structural modifications of RITA may help not only to increase the effectiveness of its binding to MDM2 and p53, but also to elucidate the common structural features of p53 and MDM2 in order to improve the anti-cancer activity of a new family of RITA-derived drugs.
Materials and methods
The X-ray structure of human MDM2 in complex with the p53 transactivation domain was used in the present study (PDB code: 1YCR). For docking purposes, the p53 fragment was removed from the original PDB file. Hydrogen atoms were added to the protein and the structure was minimized by 500 steps using the conjugate gradient protocol and employing the CHARMM27 force field implemented in NAMD 2.5 software . Subsequently, non-polar hydrogens were merged from the protein and Kollman united atom charges were assigned. Finally, the protein was equipped with fragmental volumes and solvation parameters.
The structure of RITA [2,5-bis(5-hydroxymethyl-2-thienyl)furan] (Figure 1) was optimized at the AM1 semiempirical level, and the Gasteiger-Marsili formalism  was employed to derive the partial charges on the atoms. The AUTOTORS utility, included in the latest version of AutoDock (3.0.5) , was used to define the torsions of RITA.
Docking simulations were carried out in two stages using version 3.0.5 of the AutoDock program . This program is one of the most reliable docking tools available today because it uses the efficient Lamarckian Genetic algorithm and its scoring function comprises several terms (van der Waals, coulomb potential electrostatics, directional hydrogen bonding, a volume-based solvation term and an estimation of the entropic cost of binding through a weighted sum or torsional degrees of freedom). In addition, the possible binding site need not be specified since the algorithm allows the entire surface of the target to be searched efficiently.
The grid maps representing the protein were calculated with the aid of AutoGrid, a utility of the AutoDock software. Two different grid maps with different dimensions were calculated for the protein. In the first stage, a cubic box of 120 × 120 × 120 points, with a spacing of 0.35 Å between the grid points and centered on the geometric center of the protein, was calculated in order to carry out the "blind docking" experiment. The dimensions of the box were sufficient to cover the entire surface of MDM2. In the second stage, a smaller box (50 × 50 × 50 points, spacing 0.35 Å) was built centered on the most populated binding site, using its geometric center as a reference. This smaller box was employed for performing "fine docking" on the most populated binding site found during the "blind docking" stage. In both cases, docking simulations were carried out using the Lamarckian Genetic Algorithm with an initial population of 300 individuals, a maximum number of 50,000,000 energy evaluations, a maximum number of 50,000 generations, a translation step of 2 Å, a quarternion step of 50° and a torsion step of 50°. For each local search, the pseudo-Solis and Wets algorithm was applied using a maximum number of 300 iterations. Both the blind and refined docking simulations consisted of 100 independent runs. Resulting orientations lying within 2.0 Å in the RMSD were clustered together and represented by the orientation with the most favorable free energy of binding.
The author would like to thank David D. Thomas for his hospitality and encouragement, the Minnesota Supercomputing Institute for providing computer resources and Asya Varbanova for her thorough review of the draft and suggested improvements. The author is partially supported by a research fellowship granted by the Department of Biochemisty, Structural Biology and Biophysics-University of Minnesota.
- Levine AJ: P53, the cellular gatekeeper for growth and division. Cell. 1997, 88: 323-331. 10.1016/S0092-8674(00)81871-1.View ArticlePubMedGoogle Scholar
- Wu L, Levine AJ: Differential regulation of the p21/WAF-1 and MDM2 genes after high-dose UV radiation: p53-dependent and p53-independent regulation of the MDM2 gene. Mol Med. 1997, 3: 441-451.PubMed CentralPubMedGoogle Scholar
- Vousden KH, Lu X: Live or let die: the cell's response to p53. Nat Rev Cancer. 2001, 2: 594-604. 10.1038/nrc864.View ArticleGoogle Scholar
- Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature. 2000, 408: 307-310. 10.1038/35042675.View ArticlePubMedGoogle Scholar
- Momand J, Jung D, Wilczynski S, Niland J: The MDM2 gene amplification database. Nucleic Acid Res. 1998, 26: 3453-3459. 10.1093/nar/26.15.3453.PubMed CentralView ArticlePubMedGoogle Scholar
- Chene P: Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer. 2003, 3: 102-109. 10.1038/nrc991.View ArticlePubMedGoogle Scholar
- Chene P: Inhibition of the p53-MDM2 interaction: Targeting a protein-protein interface. Mol Cancer Res. 2004, 2: 20-28.PubMedGoogle Scholar
- Chene P: Inhibition of the p53-HDM2 interaction with low molecular weight compounds. Cell Cycle. 2004, 3: 460-461.View ArticlePubMedGoogle Scholar
- Klein C, Vassilev LT: Targeting the p53-MDM2 interaction to treat cancer. Br J Cancer. 2004, 91: 1415-1319.PubMed CentralPubMedGoogle Scholar
- Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004, 303: 844-848. 10.1126/science.1092472.View ArticlePubMedGoogle Scholar
- Parks DJ, Lafrance LV, Calvo RR, Milkiewicz KL, Gupta V, Lattanze J, Ramachandren K, Carver TE, Petrella EC, Cummings MD, Maguire D, Grasberger BL, Lu T: 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR. Bioorg Med Chem Lett. 2005, 15: 765-770. 10.1016/j.bmcl.2004.11.009.View ArticlePubMedGoogle Scholar
- Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, Koblish HK, Cummings MD, LaFrance LV, Milkiewicz KL, Calvo RR, Maguire D, Lattanze J, Franks CF, Zhao S, Ramachandren K, Bylebyl GR, Zhang M, Manthey CL, Petrella EC, Pantoliano MW, Deckman IC, Spurlino JC, Maroney AC, Tomczuk BE, Molloy CJ, Bone RF: Discovery and co-crystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem. 2005, 48: 909-912. 10.1021/jm049137g.View ArticlePubMedGoogle Scholar
- Raboisson P, Marugan JJ, Schubert C, Koblish HK, Lu T, Zhao S, Player MR, Maroney AC, Reed RL, Huebert ND, Lattanze J, Parks DJ, Cummings MD: Structure based design, synthesis, and biological evaluation of novel 1,4-diazepines as HDM2 antagonists. Bioorg Med Chem Lett. 2005, 15: 1857-1861. 10.1016/j.bmcl.2005.02.018.View ArticlePubMedGoogle Scholar
- Hardcastle IS, Ahmed SU, Atkins H, Calvert AH, Curtin NJ, Farnie G, Golding BT, Griffin RJ, Guyenne S, Hutton C, Kallblad P, Kemp SJ, Kitching MS, Newell DR, Norbedo S, Northen JS, Reid RJ, Saravanan K, Willems HM, Lunec J: Isoindolinone based inhibitors of the MDM2-p53 protein-protein interaction. Bioorg Med Chem Lett. 2005, 15: 1515-1520. 10.1016/j.bmcl.2004.12.061.View ArticlePubMedGoogle Scholar
- Kritzer JA, Hodsdon ME, Schepartz A: Solution structure of a β-peptide ligand for HDM2. J Am Chem Soc. 2005, 5127: 4118-4119. 10.1021/ja042933r.View ArticleGoogle Scholar
- Zhong H, Carlson HA: Computational studies and peptidomimetic design for the human p53-MDM2 complex. Proteins. 2005, 58: 222-234. 10.1002/prot.20275.View ArticlePubMedGoogle Scholar
- Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G: Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med. 2004, 10: 1321-1328. 10.1038/nm1146.View ArticlePubMedGoogle Scholar
- Espinoza-Fonseca LM: The benefits of multi-target approach in drug design and discovery. Bioorg Med Chem. 2005,Google Scholar
- Hetenyi C, van der Spoel D: Efficient docking of peptides to proteins without prior knowledge of the binding site. Protein Sci. 2002, 11: 1729-1737. 10.1110/ps.0202302.PubMed CentralView ArticlePubMedGoogle Scholar
- Schon O, Friedler A, Freund S, Fersht AR: Binding of p53-derived ligands to MDM2 induces a variety of long-range conformational changes. J Mol Biol. 2004, 336: 197-202. 10.1016/j.jmb.2003.11.051.View ArticlePubMedGoogle Scholar
- Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP: Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996, 274: 948-53. 10.1126/science.274.5289.948.View ArticlePubMedGoogle Scholar
- Burch LR, Midgley CA, Currie RA, Lane DP, Hupp TR: Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA. FEBS Lett. 2000, 472: 93-98. 10.1016/S0014-5793(00)01427-7.View ArticlePubMedGoogle Scholar
- Van Regenmortel MH: Molecular recognition in the post-reductionist era. J Mol Recognit. 1999, 12: 1-2. 10.1002/(SICI)1099-1352(199901/02)12:1<1::AID-JMR449>3.0.CO;2-P.View ArticlePubMedGoogle Scholar
- Stephenson VC, Heyding RA, Weaver DF: The "promiscuous drug concept" with applications to Alzheimer's disease. FEBS Lett. 2005, 579: 1338-1342. 10.1016/j.febslet.2005.01.019.View ArticlePubMedGoogle Scholar
- Kale L, Skeel R, Bhandarkar M, Brunner R, Gursoy A, Krawetz N, Phillips J, Shinozaki A, Varadarajan K, Schulten K: NAMD2: Greater scalability for parallel molecular dynamics. J Comput Phys. 1999, 151: 283-10.1006/jcph.1999.6201.View ArticleGoogle Scholar
- Gasteiger J, Marsili M: Iterative partial equalization of orbital electronegativity – a rapid access to atomic charges. Tetrahedron. 1980, 36: 3219-3228. 10.1016/0040-4020(80)80168-2.View ArticleGoogle Scholar
- Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ: Automated docking using Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem. 1998, 19: 1639-1662. 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.